Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.Neurology|June 8, 2018
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched studyLuca Prosperini, Matteo Lucchini, Shalom Haggiag, et al.Journal of Neurology|November 14, 2019
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison studyLuca Prosperini, Antonio Cortese, Matteo Lucchini, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 27, 2020
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter studyFrancesco Patti, Clara Grazia Chisari, Claudio Solaro, et al.Journal of Neurology, Neurosurgery, and Psychiatry|July 15, 2020
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre studyClara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, et al.Neurology|November 3, 2017
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter studyAlice Laroni, Alessio Signori, Giorgia T Maniscalco, et al.Multiple Sclerosis and Related Disorders|March 26, 2020
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian studyGiorgia T Maniscalco, Francesco Saccà, Roberta Lanzillo, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2018
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life studyFrancesco Saccà, Roberta Lanzillo, Alessio Signori, et al.Neurology(R) Neuroimmunology & Neuroinflammation|August 18, 2020
Cladribine vs other drugs in MS: Merging randomized trial with real-life dataAlessio Signori, Francesco Saccà, Roberta Lanzillo, et al.Pageof 3